ファブリー病治療市場- 世界の産業規模、シェア、動向、機会、予測、薬剤別、治療別、投与経路別、流通チャネル別、地域別セグメント、競合、2020年～2030年

世界のファブリー病治療市場は2024年に18億6,000万米ドルと評価され、2030年までのCAGRは6.30%で、予測期間中に目覚ましい成長を遂げると予測されています。

ファブリー病は、アンダーソン・ファブリー病としても知られ、ライソゾーム貯蔵障害として知られる疾患群に属するまれな遺伝性疾患です。この疾患は、α-ガラクトシダーゼA（α-Gal A）と呼ばれる酵素をコードするGLA遺伝子の変異によって引き起こされます。この酵素が欠損すると、グロボトリアオシルセラミド（Gb3またはGL-3）として知られる特定のタイプの脂肪物質が全身の細胞内に蓄積します。このGb3の蓄積は主に血管、腎臓、心臓、神経系の細胞に影響を及ぼし、様々な症状や合併症を引き起こします。ファブリー病の症状は多くの場合、小児期または青年期に現れるが、症状の発現年齢や重症度は罹患者によって大きく異なります。ファブリー病の特徴的な症状の一つは神経障害性疼痛で、重篤で慢性化することがあります。この痛みは通常、手や足などの四肢に起こり、しばしば灼熱感や疼きと表現されます。例えば、全米ファブリー病財団（NFDF）によると、米国では毎年4月をファブリー病啓発月間としています。啓発プログラムは、一般市民、患者、介護者、ヘルスケア専門家の教育に重点を置いています。これらのイニシアチブは、ファブリー病の理解、診断、管理を改善することを目的としており、最終的には調査期間を通じて市場の成長に寄与します。

市場促進要因

診断の進歩

主な市場課題

限られた患者数

主要市場動向

バイオマーカー開発

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のファブリー病治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 薬剤別（アガルシダーゼベータ、ミガラスタット、その他）
  • 治療別（酵素補充療法（ERT）、シャペロン治療、基質還元療法（SRT）、その他）
  • 投与経路別（経口、非経口、その他）
  • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 アジア太平洋地域のファブリー病治療市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州のファブリー病治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米のファブリー病治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米のファブリー病治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのファブリー病治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界のファブリー病治療市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTEL分析

第16章 競合情勢

• Sanofi（Genzyme Corporation）
• Takeda Pharmaceutical Company Limited
• Amicus Therapeutics, Inc
• JCR Pharmaceuticals Co., Ltd.
• Protalix BioTherapeutics Inc.
• Chiesi Farmaceutici S.p.A.
• Freeline Therapeutics Holdings PLC
• Yuhan Corporation
• M6P Therapeutics
• ISU Abxis Co Ltd

第17章 戦略的提言

第18章 調査会社について・免責事項

Global Fabry Disease Treatment Market was valued at USD 1.86 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 6.30% through 2030. Fabry disease, also known as Anderson-Fabry disease, is a rare and inherited genetic disorder that belongs to a group of conditions known as lysosomal storage disorders. This disease is caused by mutations in the GLA gene, which encodes an enzyme called alpha-galactosidase A (alpha-Gal A). The deficiency of this enzyme results in the accumulation of a specific type of fatty substance, known as globotriaosylceramide (Gb3 or GL-3), within cells throughout the body. This buildup of Gb3 primarily affects the cells of blood vessels, kidneys, heart, and nervous system, leading to a wide range of symptoms and complications. Symptoms of Fabry disease often appear in childhood or adolescence, although the age of symptom onset and their severity can vary widely among affected individuals. One of the hallmark symptoms of Fabry disease is neuropathic pain, which can be severe and chronic. This pain typically affects the extremities, such as the hands and feet, and is often described as burning or tingling. For instance, according to the National Fabry Disease Foundation (NFDF) designates April as Fabry Disease Awareness Month each year in the United States. Awareness programs focus on educating the public, patients, caregivers, and healthcare professionals. These initiatives aim to improve the understanding, diagnosis, and management of Fabry disease, ultimately contributing to market growth throughout the study period.

Key Market Drivers

Advancements in Diagnosis

Genetic testing has become a cornerstone in the diagnosis of Fabry disease. Advances in genetic sequencing technology have made it more accessible and cost-effective to identify specific mutations in the GLA gene, which is responsible for the disease. Genetic testing can confirm the presence of Fabry disease and provide information about the specific genetic mutations involved. In some regions, newborn screening programs have been implemented to identify Fabry disease in infants shortly after birth. This early detection allows for prompt intervention and treatment, potentially preventing or delaying the onset of symptoms and organ damage. Researchers have been investigating biomarkers associated with Fabry disease. Biomarkers are measurable substances in the body that can indicate the presence of a disease or its progression. Biomarker research can aid in early diagnosis and monitoring the effectiveness of treatment. Clinical diagnostic criteria for Fabry disease have been refined and standardized. Healthcare professionals now have clearer guidelines and criteria to assist in diagnosing disease based on clinical symptoms and genetic testing results. For instance, in December 2022, Bio Sidus SA sponsored a clinical trial to assess the efficacy and safety of AGA BETA BS in FD patients previously stabilized with Fabrazyme. Also, Fabry disease pipeline products continue to drive market growth. For example, in August 2021, the European Commission approved Amicus Therapeutics' Galafold for long-term treatment of Fabry disease in patients aged 12 and above with an amenable mutation.

Key Market Challenges

Limited Patient Population

The small patient population with Fabry disease results in a limited market size for pharmaceutical companies. This can make it less economically attractive for these companies to invest in research and development of treatments for disease. Developing and gaining regulatory approval for new treatments, including clinical trials and research, is costly. In the case of rare diseases like Fabry disease, the small number of potential patients can make it challenging to recoup these expenses. Due to the small market size, the revenue potential for treatments for Fabry disease may be limited compared to drugs for more common conditions. This can affect the profitability of drug development efforts. Limited patient populations can result in challenges related to patient access to treatments and affordability. Even if effective treatments exist, they may not be accessible to all patients due to cost or availability. The rarity of Fabry disease can lead to delayed diagnosis or misdiagnosis, as healthcare providers may not be familiar with the condition. This can result in patients not receiving appropriate treatment until the disease has progressed. Limited patient populations can also result in a scarcity of clinical data on the disease and its treatment. This can make it challenging for healthcare providers to make informed treatment decisions. Recognizing the challenges posed by rare diseases, some regulatory agencies provide incentives for orphan drug development. These incentives can include extended market exclusivity and reduced regulatory fees.

Key Market Trends

Biomarker Development

Biomarkers can aid in the early diagnosis of Fabry disease, allowing for timely intervention and treatment initiation. Early diagnosis is essential for preventing or delaying the onset of symptoms and organ damage. Biomarkers can be used to monitor disease progression and assess the effectiveness of treatment over time. This enables healthcare providers to tailor treatment plans to individual patients' needs. Certain biomarkers may be associated with the severity of Fabry disease. Identifying these biomarkers can help predict disease outcomes and guide treatment decisions. Biomarkers can help determine how well a patient is responding to treatment. If treatment is effective, biomarkers may show improvements in disease-related indicators. Biomarkers can serve as valuable endpoints in clinical trials of new Fabry disease treatments. They provide objective measures of treatment efficacy and safety. The development of biomarkers supports the concept of personalized medicine, where treatments are tailored to individual patients based on their biomarker profiles. This approach can optimize treatment outcomes. Biomarkers provide insights into the underlying molecular and genetic mechanisms of Fabry disease. This knowledge can inform drug development efforts, leading to more targeted and effective therapies. Biomarkers can be used to stratify Fabry disease patients into different subgroups based on disease characteristics. This stratification can guide treatment decisions and improve patient outcomes. Biomarkers can help reduce diagnostic delays by providing objective evidence of Fabry disease. This is particularly important because Fabry disease is often underdiagnosed or misdiagnosed.

Key Market Players

• Sanofi (Genzyme Corporation)
• Takeda Pharmaceutical Company Limited
• Amicus Therapeutics, Inc
• ISU ABXIS Co Ltd.
• JCR Pharmaceuticals Co., Ltd.
• Protalix BioTherapeutics Inc.
• Chiesi Farmaceutici S.p.A.
• Freeline Therapeutics Holdings PLC
• Yuhan Corporation
• M6P Therapeutics Inc.

Report Scope:

In this report, the Global Fabry Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Fabry Disease Treatment Market, By Drugs:

• Agalsidase Beta
• Migalastat
• others

Fabry Disease Treatment Market, By Treatment:

• Enzyme Replacement Therapy (ERT)
• Chaperone Treatment
• Substrate Reduction Therapy (SRT)
• Others

Fabry Disease Treatment Market, By Route of Administration:

• Oral
• Parenteral
• Others

Fabry Disease Treatment Market, By Distribution Channel:

• Hospital pharmacies
• Retail pharmacies
• Online Pharmacies

Fabry Disease Treatment Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Fabry Disease Treatment Market.

Available Customizations:

Global Fabry Disease Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Fabry Disease Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drugs (Agalsidase Beta, Migalastat, others)
  • 5.2.2. By Treatment (Enzyme Replacement Therapy (ERT), Chaperone Treatment, Substrate Reduction Therapy (SRT), others)
  • 5.2.3. By Route of Administration (Oral, Parenteral, others)
  • 5.2.4. By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online Pharmacies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Fabry Disease Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drugs
  • 6.2.2. By Treatment
  • 6.2.3. By Route of Administration
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Fabry Disease Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drugs
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. India Fabry Disease Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drugs
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Australia Fabry Disease Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drugs
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Distribution Channel
  • 6.3.4. Japan Fabry Disease Treatment Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Drugs
      • 6.3.4.2.2. By Treatment
      • 6.3.4.2.3. By Route of Administration
      • 6.3.4.2.4. By Distribution Channel
  • 6.3.5. South Korea Fabry Disease Treatment Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Drugs
      • 6.3.5.2.2. By Treatment
      • 6.3.5.2.3. By Route of Administration
      • 6.3.5.2.4. By Distribution Channel

7. Europe Fabry Disease Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drugs
  • 7.2.2. By Treatment
  • 7.2.3. By Route of Administration
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Fabry Disease Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drugs
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. Germany Fabry Disease Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drugs
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. Spain Fabry Disease Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drugs
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Fabry Disease Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drugs
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. United Kingdom Fabry Disease Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drugs
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Distribution Channel

8. North America Fabry Disease Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drugs
  • 8.2.2. By Treatment
  • 8.2.3. By Route of Administration
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Fabry Disease Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drugs
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. Mexico Fabry Disease Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drugs
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Canada Fabry Disease Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drugs
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Distribution Channel

9. South America Fabry Disease Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drugs
  • 9.2.2. By Treatment
  • 9.2.3. By Route of Administration
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Fabry Disease Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drugs
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. Argentina Fabry Disease Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drugs
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. Colombia Fabry Disease Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drugs
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Distribution Channel

10. Middle East and Africa Fabry Disease Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drugs
  • 10.2.2. By Treatment
  • 10.2.3. By Route of Administration
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Fabry Disease Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drugs
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Saudi Arabia Fabry Disease Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drugs
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. UAE Fabry Disease Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drugs
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Fabry Disease Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Sanofi (Genzyme Corporation)
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Takeda Pharmaceutical Company Limited
  • 16.2.1. Business Overview
  • 16.2.2. Company Snapshot
  • 16.2.3. Products & Services
  • 16.2.4. Financials (In case of listed companies)
  • 16.2.5. Recent Developments
  • 16.2.6. SWOT Analysis
• 16.3. Amicus Therapeutics, Inc
  • 16.3.1. Business Overview
  • 16.3.2. Company Snapshot
  • 16.3.3. Products & Services
  • 16.3.4. Financials (In case of listed companies)
  • 16.3.5. Recent Developments
  • 16.3.6. SWOT Analysis
• 16.4. JCR Pharmaceuticals Co., Ltd.
  • 16.4.1. Business Overview
  • 16.4.2. Company Snapshot
  • 16.4.3. Products & Services
  • 16.4.4. Financials (In case of listed companies)
  • 16.4.5. Recent Developments
  • 16.4.6. SWOT Analysis
• 16.5. Protalix BioTherapeutics Inc.
  • 16.5.1. Business Overview
  • 16.5.2. Company Snapshot
  • 16.5.3. Products & Services
  • 16.5.4. Financials (In case of listed companies)
  • 16.5.5. Recent Developments
  • 16.5.6. SWOT Analysis
• 16.6. Chiesi Farmaceutici S.p.A.
  • 16.6.1. Business Overview
  • 16.6.2. Company Snapshot
  • 16.6.3. Products & Services
  • 16.6.4. Financials (In case of listed companies)
  • 16.6.5. Recent Developments
  • 16.6.6. SWOT Analysis
• 16.7. Freeline Therapeutics Holdings PLC
  • 16.7.1. Business Overview
  • 16.7.2. Company Snapshot
  • 16.7.3. Products & Services
  • 16.7.4. Financials (In case of listed companies)
  • 16.7.5. Recent Developments
  • 16.7.6. SWOT Analysis
• 16.8. Yuhan Corporation
  • 16.8.1. Business Overview
  • 16.8.2. Company Snapshot
  • 16.8.3. Products & Services
  • 16.8.4. Financials (In case of listed companies)
  • 16.8.5. Recent Developments
  • 16.8.6. SWOT Analysis
• 16.9. M6P Therapeutics
  • 16.9.1. Business Overview
  • 16.9.2. Company Snapshot
  • 16.9.3. Products & Services
  • 16.9.4. Financials (In case of listed companies)
  • 16.9.5. Recent Developments
  • 16.9.6. SWOT Analysis
• 16.10.ISU Abxis Co Ltd
  • 16.10.1. Business Overview
  • 16.10.2. Company Snapshot
  • 16.10.3. Products & Services
  • 16.10.4. Financials (In case of listed companies)
  • 16.10.5. Recent Developments
  • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer